DE69630682D1 - Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes - Google Patents

Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes

Info

Publication number
DE69630682D1
DE69630682D1 DE69630682T DE69630682T DE69630682D1 DE 69630682 D1 DE69630682 D1 DE 69630682D1 DE 69630682 T DE69630682 T DE 69630682T DE 69630682 T DE69630682 T DE 69630682T DE 69630682 D1 DE69630682 D1 DE 69630682D1
Authority
DE
Germany
Prior art keywords
treatment
systemic lupus
synthetic peptides
peptides
medicinal products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69630682T
Other languages
English (en)
Other versions
DE69630682T2 (de
Inventor
Edna Mozes
Ari Waisman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of DE69630682D1 publication Critical patent/DE69630682D1/de
Publication of DE69630682T2 publication Critical patent/DE69630682T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE69630682T 1995-03-28 1996-03-27 Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes Expired - Lifetime DE69630682T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11315995A IL113159A0 (en) 1995-03-28 1995-03-28 Synthetic peptides and pharmaceutical compositions comprising them
IL11315995 1995-03-28
PCT/US1996/004206 WO1996030057A1 (en) 1995-03-28 1996-03-27 Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
DE69630682D1 true DE69630682D1 (de) 2003-12-18
DE69630682T2 DE69630682T2 (de) 2004-09-16

Family

ID=11067281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69630682T Expired - Lifetime DE69630682T2 (de) 1995-03-28 1996-03-27 Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes

Country Status (11)

Country Link
EP (1) EP0817650B1 (de)
JP (1) JP3862752B2 (de)
AT (1) ATE253944T1 (de)
AU (1) AU706772B2 (de)
CA (1) CA2217776C (de)
DE (1) DE69630682T2 (de)
DK (1) DK0817650T3 (de)
ES (1) ES2212801T3 (de)
IL (2) IL113159A0 (de)
PT (1) PT817650E (de)
WO (1) WO1996030057A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU773891C (en) 1998-10-23 2005-02-17 Kirin-Amgen Inc. Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
IL141647A0 (en) 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
EP1511772B1 (de) * 2002-05-28 2011-11-23 Omrix Biopharmaceuticals Inc. Verfahren zum erhalten von anti-idiotyp antikörpern
KR20050100616A (ko) * 2003-01-14 2005-10-19 테바 파마슈티컬 인더스트리즈 리미티드 전신성 홍반성 낭창의 치료를 위한 펩티드의 비경구 제제
CN1774259B (zh) * 2003-01-14 2011-12-28 特瓦制药工业有限公司 治疗系统性红斑狼疮的肽的胃肠道外制剂
EP1773400A2 (de) 2004-07-08 2007-04-18 Amgen Inc. Therapeutische peptide
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021367A1 (en) * 1991-05-31 1992-12-10 Arthur Allen Vandenbark T cell receptor peptides as therapeutics for immune-related disease

Also Published As

Publication number Publication date
ES2212801T3 (es) 2004-08-01
CA2217776A1 (en) 1996-10-03
PT817650E (pt) 2004-03-31
WO1996030057A1 (en) 1996-10-03
ATE253944T1 (de) 2003-11-15
JPH11503124A (ja) 1999-03-23
DE69630682T2 (de) 2004-09-16
DK0817650T3 (da) 2004-03-08
EP0817650A4 (de) 1999-09-01
JP3862752B2 (ja) 2006-12-27
IL113159A0 (en) 1995-06-29
EP0817650B1 (de) 2003-11-12
AU5433496A (en) 1996-10-16
CA2217776C (en) 2004-12-07
EP0817650A1 (de) 1998-01-14
IL117686A (en) 2000-10-31
IL117686A0 (en) 1996-07-23
AU706772B2 (en) 1999-06-24

Similar Documents

Publication Publication Date Title
RU2220980C2 (ru) Химерное антитело, которое связывается с cd40 человека (варианты), молекула нуклеиновой кислоты (варианты), вектор экспрессии (варианты), гуманизированное антитело (варианты), фармацевтическая композиция для лечения заболевания, опосредованного т-клетками (варианты), способ лечения больного от заболевания, опосредованного т-клетками (варианты)
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
DE69630682D1 (de) Synthetische peptide und diese enthaltende arzneimittel zur behandlung des systemischen lupus erythematodes
HK1154604A1 (en) Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system igm
DE69232263T2 (de) Radikalfänger ("spin traps") zur behandlung von mit oxidation von lipiden und proteinen verbundenen erkrankungen
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
DK0845998T3 (da) Lægemidler til immunbehandling indeholdende antistoffer, der specifikt genkender MHCII-antigenet hos en patient, der skal behandles
DK1057826T3 (da) Substituerede dimere carboxamidforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske sammensætninger indeholdende disse
EA200000240A1 (ru) Соединения, препятствующие эффекту раннего превращения лекарственных средств
FR2718451B1 (fr) Dérivés de peptides boroniques, leur préparation et leur application en thérapeutique.
ATE346094T1 (de) Synthetische humane peptide und diese enthaltende pharmazeutische zusammensetzungen zur behandlung von systemischem lupus erythematodes
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
DE58909594D1 (de) 6-Oxo-pyridazinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
FR2694938B1 (fr) Nouveaux peptides, anticorps diriges contre ces peptides, anticorps anti-idiotypiques, application a titre de medicaments, compositions pharmaceutiques et kits de diagnostic les renfermant.
ATE192164T1 (de) Synthetische peptide und diese enthaltende pharmazeutische zusammensetzungen
ATE283290T1 (de) Verwendung von substanzen mit immunmodulatorischer wirkung für die behandlung der amyotrophen lateralsklerose
DE69811253D1 (de) Osteoblastenspezifische mitogene und diese verbindungen enthaltende arzneimittel
DE69630948T2 (de) Peptide und medikamente für knochenkrankheiten welche diese peptide als aktive bestandteile beinhalten
FR2699172B1 (fr) Nouveaux dérivés de 4-méthyl-1,3-oxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2709126B1 (fr) Nouveaux dérivés de naphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2707648B1 (fr) Antagonistes de la Cholecystokinine, leur procédé de préparation et les compositions pharmaceutiques les comprenant.
FR2696175B1 (fr) Nouveaux dérivés chroméniques à chaîne triénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
FR2672617B1 (fr) Sequences nucleotidiques codant pour des regions variables de chaines beta des recepteurs des lymphocytes t humains, segments peptidiques correspondants et les applications diagnostiques et therapeutiques.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition